Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 20/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 19/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20723396 | 1.00 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL20721499 | 0.86 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL23897087 | 0.85 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL24437191 | 0.83 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL20721455 | 0.83 | PRMT5 (0.44) | PRMT5WDR77 | |
| SCHEMBL23897086 | 0.81 | PRMT5 (0.42) | PRMT5WDR77 | |
| SCHEMBL24489756 | 0.80 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL21367163 | 0.80 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL21367135 | 0.80 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL21367292 | 0.80 | PRMT5 (0.41) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3939986-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | Prelude Therapeutics, Incorporated (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3665179-B1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2019032859-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2019-02-14 | — | — | WO | disclosed |